Neoadjuvant chemotherapy and radiotherapy in locally advanced XXXX : long-term results.

@entity1 @entity137 @entity7324 @entity5 @entity957 @entity900 @entity189 @entity1732
PURPOSE: A prospective study with neoadjuvant chemotherapy and radiotherapy in @entity1 with locally advanced @entity189 for evaluating: @entity137 , response rate, pattern of recurrence, and survival after a long follow-up. METHODS AND MATERIALS: Between 1983-1988, 40 @entity1 with locally advanced @entity957 of the thoracic esophagus were entered into a prospective trial of neoadjuvant chemotherapy and radiotherapy. Eight @entity1 (20%) were Stage II and 32 @entity1 (80%) were Stage III, according to American Joint Committee staging criteria. Neoadjuvant chemotherapy consisted of two cycles with @entity900 (120 mg/m2 day 1), @entity7324 (3 mg/m2 days 1, 8, 15, and 22) and @entity1732 (10 mg/m2 days 3 to 6). Second cycle was initiated on day 29. Radiation therapy was administered 2-4 weeks after completion of chemotherapy, with a total dose on @entity5 of 60 Gy. RESULTS: Two @entity1 died from treatment-related @entity137 . Complete response was observed in 20 @entity1 (53%) and symptomatic improvement in 31 @entity1 (82%). The median survival was 11 months, with an actuarial survival at 1 year of 45%, 3 year 20%, and 5 years 15%. Significantly (p < 0.05) longer survival was observed in @entity1 with Stage II (median survival 18 months) vs. Stage III (median survival 10 months). The pattern of failure was predominantly local/regional (62%). CONCLUSION: This treatment scheme is an effective and tolerable regimen but long-term survival was poor.
